

Robust immunogenicity of a third BNT162b2 vaccination against SARS-CoV-2 Omicron variant in a naïve New Zealand cohort

Authors:

Brittany Lavender^a, Caitlin Hooker^a, Chris Frampton^b, Michael Williams^c, Simon Carson^c, Aimee Paterson^d, Reuben McGregor^d, Nicole J. Moreland^d, Katie Gell^a, Frances H. Priddy^f, Kjesten Wiig^a, Graham Le Gros^a, James E. Ussher^g, Maia Brewerton^{a,e}

Affiliations:

^a Vaccine Alliance Aotearoa New Zealand and Malaghan Institute of Medical Research, PO Box 7060, Wellington 6242, New Zealand

^b University of Otago, 2 Riccarton Ave, Christchurch 8011, New Zealand

^c Pacific Clinical Research Network, 1289 Haupapa St, Rotorua 3010, New Zealand

^d School of Medical Sciences, The University of Auckland, 2 Park Rd, Grafton, Auckland 1023, New Zealand

^e Department of Clinical Immunology & Allergy, Auckland City Hospital, 2 Park Rd, Grafton, Auckland 1023, New Zealand

^f Independent Consultant

^g Vaccine Alliance Aotearoa New Zealand and University of Otago, 362 Leith St, Dunedin 9016, New Zealand

Corresponding Author:

Dr Maia Brewerton or Brittany Lavender

Address: Malaghan Institute of Medical Research, PO Box 7060, Wellington 6242, New Zealand.

Email: blavender@malaghan.org.nz

1 *Abstract*

2 The ability of a third dose of the Pfizer-BioNTech BNT162b2 SARS-CoV-2 vaccine to stimulate immune
3 responses against subvariants, including Omicron BA.1, has not been assessed in New Zealand
4 populations. Unlike many overseas populations, New Zealanders were largely infection naïve at the time
5 they were boosted. This adult cohort of 298 participants, oversampled for at-risk populations, was
6 composed of 29% Māori and 28% Pacific peoples, with 40% of the population aged 55+. A significant
7 proportion of the cohort was obese and presented with at least one comorbidity. Sera were collected 28
8 days and 6 months post second vaccination and 28 days post third vaccination. SARS-CoV-2 anti-S IgG
9 titres and neutralising capacity using surrogate viral neutralisation assays against variants of concern,
10 including Omicron BA.1, were investigated. The incidence of SARS-CoV-2 infection, within our cohort,
11 prior to third vaccination was very low (<6%). This study found a third vaccine significantly increased the
12 mean SARS-CoV-2 anti-S IgG titres, for every demographic subgroup, by a minimum of 1.5-fold compared
13 to titres after two doses. Diabetic participants experienced a greater increase (~4-fold) in antibody titres
14 after their third vaccination, compared to non-diabetics (increase of ~2-fold). This corrected for the
15 deficiency in antibody titres within diabetic participants which was observed following two doses. A third
16 dose also induced a neutralising response against Omicron variant BA.1, which was absent after two
17 doses. This neutralising response improved regardless of age, BMI, ethnicity, or diabetes status.
18 Participants aged ≥ 75 years consistently had the lowest SARS-CoV-2 anti-S IgG titres at each timepoint,
19 however experienced the greatest improvement after three doses compared to younger participants.
20 This study shows that in the absence of prior SARS-CoV-2 infection, a third Pfizer-BioNTech BNT162b2
21 vaccine enhances immunogenicity, including against Omicron BA.1, in a cohort representative of at-risk
22 groups in the adult New Zealand population.

23

24 *Keywords*

25 SARS-CoV-2, vaccination, antibody, immunogenicity, booster, New Zealand

26

27 *Introduction*

28 It has been over three years since Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first
29 emerged in Wuhan, China, with the World Health Organization (WHO) declaring this novel coronavirus a
30 public health emergency in January 2020 [1]. As SARS-CoV-2 spread rapidly around the world causing
31 coronavirus disease (COVID-19), Aotearoa New Zealand introduced stringent public health measures in
32 pursuit of a SARS-CoV-2 elimination strategy, in March 2020 [2]. This strategy prevented the widespread
33 community transmission of SARS-CoV-2 in New Zealand before effective COVID-19 vaccines were
34 available to the public early in 2021. Therefore, prior to the introduction of Omicron and the termination
35 of the elimination strategy in early 2022, incident SARS-CoV-2 infections were rare in the wider New
36 Zealand population. This provided a unique opportunity to study the immunogenicity of a third vaccine in
37 the absence of wide-spread infection.

38

39 Until January 2022, when the highly transmissible Omicron variant entered the community [3], New
40 Zealand experienced very low rates of SARS-CoV-2 infection (<0.3% of the total population), despite a
41 controlled outbreak of the Delta variant in the Auckland region [4]. The Omicron outbreak began with the
42 BA.1 variant which was quickly overtaken by BA.2 [5, 6]. At the time of writing, the CH.1.1 and XBB
43 variants are the most prevalent Variant of Concerns (VoC) within New Zealand [7]. After the Omicron
44 variant became established in New Zealand, the epidemiology of COVID-19 mortality risk mirrored what
45 had been seen overseas, with increasing age being the strongest risk factor for death from COVID-19 in
46 New Zealand [8, 9]. Inequities in COVID-19 mortality risk were seen as Māori and Pacific peoples
47 experienced more than double the mortality risk compared to other ethnicities. If these individuals had
48 at least one comorbidity, their risk increased 6-fold compared to those without comorbidities [9].

49

50 New Zealand's nationwide COVID-19 immunisation programme began in February 2021 [3], with a
51 stepwise vaccination roll out according to eligibility criteria. The majority of New Zealander's became
52 eligible for vaccination by July 2021 [4]. Pfizer-BioNTech BNT162b2 is the preferred COVID-19 vaccine in
53 New Zealand with it comprising 99.9% (11,900,035 out of 11,916,152) of administered vaccine doses.

54 NovaVax NVX-CoV2373 and Oxford/AstraZeneca ChAdOx1 nCoV-19 doses comprise the small remainder
55 [5].

56

57 New Zealand achieved very high uptake of the COVID-19 vaccine with 89.3% of those aged 12 years and
58 over having received two doses [5]. In line with the results of international data, in November 2021 a
59 third dose was recommended by the New Zealand Government. This was initially recommended to be
60 administered 6 months after the primary two-dose schedule but, due to increasing community
61 transmission in February 2022, was brought forward to 4 months and then 3 months shortly after [6-8].
62 The uptake of the third dose has been significantly lower with 73.2% of New Zealanders aged 18 years
63 and over receiving at least three doses [9].

64

65 In this study, we present further immunogenicity findings following BNT162b2 vaccination from the
66 ongoing cohort study, Ka Mātau, Ka Ora, conducted in New Zealand. This cohort includes some of those
67 at higher risk of severe disease or death from COVID-19 including older people, Māori, Pacific peoples,
68 and those with co-morbidities. Prior results from this cohort showed an absence of neutralising capacity
69 of antibodies against Omicron (BA.1) 28 days after two BNT162b2 vaccine doses [10]. Additionally,
70 participants with diabetes showed reduced immunogenicity against SARS-CoV-2 following two doses
71 compared to non-diabetics [10]. Here we evaluate waning of antibody responses 6 months after two
72 doses of BNT162b2 and the impact of a third dose on antibody responses in a largely SARS-CoV-2
73 infection naïve cohort while comparing across age groups, ethnicities, and co-morbidities.

74

75

76

77 *Methods*

78 *Study Design and Population*

79 In this ongoing cohort study, Ka Mātau, Ka Ora, a total of 298 adult participants were enrolled at study
80 commencement in June 2021. There is an enrichment of at-risk populations in New Zealand in the cohort,
81 including Māori, Pacific peoples, adults over 65 years of age, and those with comorbidities associated
82 with a greater risk of severe COVID-19 disease. Comorbidities recorded include cardiac, pulmonary,
83 endocrine and haematologic conditions. Participants with primary or secondary immunodeficiencies
84 were excluded, and key inclusion and exclusion criteria are as published [10]. Participant recruitment
85 occurred outside of New Zealand's most populated area (the Auckland region) at two Pacific Clinical
86 Research Network locations in Rotorua (North Island) and Christchurch (South Island). Participants were
87 administered two primary doses, and a third dose of the Pfizer-BioNTech BNT162b2 vaccine, between
88 June 2021 and April 2022, in accordance with New Zealand's national COVID-19 immunisation
89 programme. Blood serum samples were collected 28 days after the second dose, 6 months after the
90 second dose (and prior to the third dose therefore this collection was brought forward in participants
91 who received their third dose between 3 and 6 months) and 28 days post third vaccine dose. Vaccination
92 dates were self-reported by participants and confirmed on vaccination cards where available.

93

94 *Ethical Approval*

95 The New Zealand Health and Disability Ethics Committee granted approval for the original design of the
96 Ka Mātau, Ka Ora Study and its analyses in June 2021 (21/NTB/117). Approval of amendments to the
97 study design incorporating third vaccine doses were granted in December 2021.

98

99 *Demographic Variables*

100 Key variables analysed in this cohort were age, gender, ethnicity, body mass index (BMI), and
101 comorbidities, including diabetes status. Age was defined at time of enrolment based on year of birth.
102 Participant age was not altered as part of the longitudinal study, which continued over an approximate
103 12-month period. Prioritised ethnicity was self-reported by participants using the categories provided as

104 part of the New Zealand Ethnicity Protocols [11]. Participant BMIs were categorised in accordance with
105 the New Zealand Ministry of Health guidelines: 18.5 kg/m² - 24.9 kg/m² (healthy weight), 25.0 kg/m² -
106 29.9 kg/m² (overweight) and ≥ 30.0 kg/m² (obese) [12].

107

108 *Laboratory Analysis*

109 *Anti-SARS-CoV-2- nucleocapsid specific antibodies (including IgG)*

110 Serum samples were analysed at Southern Community Laboratories in Dunedin (New Zealand). The
111 electrochemiluminescence Elecsys® Anti-SARS-CoV-2 immunoassay (Roche Ltd) was used, in accordance
112 with manufacturer instructions, to detect antibodies that recognise SARS-CoV-2 nucleocapsid protein in
113 serum, which indicates prior infection [13]. Participants were tested at baseline (pre vaccination), prior to
114 third dose and 28 days post third vaccine dose. The manufacturer's cut-off for a reactive sample (COI > 1)
115 was used.

116

117 *SARS-CoV-2 anti-S IgG antibodies*

118 Binding antibodies specific to the Ancestral SARS-CoV-2 spike protein were quantified using the Abbott
119 SARS-CoV-2 IgG II Quant immunoassay (Abbott Laboratories, Abbott Park, USA). This was conducted at
120 Southern Community Laboratories, according to manufacturer's instructions as previously described [13].
121 The manufacturer's cut off for a positive sample remains as 50 AU/mL. Quantitative titres were
122 converted to WHO International Units using a conversion factor supplied by the manufacturer.

123

124 *Neutralising SARS-CoV-2 antibodies*

125 Neutralising antibodies against Ancestral, Beta, Delta, and Omicron BA.1 variants of SARS-CoV-2 were
126 quantified using the cPass SARS-CoV-2 Surrogate Virus Neutralisation Test (sVNT) (Genscript, Singapore),
127 in accordance with the manufacturer's guidelines at the University of Auckland (New Zealand). This assay
128 is validated against live viral neutralisation assays, and measures reduction in binding of recombinant
129 spike and ACE2 proteins as a surrogate for neutralisation of viral infection [13, 14]. Results were reported
130 as percent (%) inhibition for all VoC. A value below 20% indicates a negative result.

131

132 *Statistical Methods*

133 Anti-S IgG are reported as Geometric Mean Titres (GMT). Geometric Mean Fold Rise (GMFR) describes
134 the change in GMT of anti-S IgG between two different time points. Values were adjusted for
135 demographic variables, BMI, age, ethnicity, and diabetes. Change (Δ) in % inhibition between 6 months
136 post second dose and 28 days post third dose was calculated for the sVNT assay results.

137

138 All participants with datapoints were included in the analysis for each timepoint and each variable
139 measured, with no missing data imputation for sporadic missing assay values. Sample sizes and
140 demographic features therefore differed slightly depending on the timepoint and assay values analysed,
141 as indicated within the descriptive tables. The immunogenicity and neutralisation values were
142 transformed prior to analysis to normalise distributions and analysed using general linear models,
143 including age, BMI, ethnicity, and diabetes as covariates. Tabled results represent model-derived, back-
144 transformed means and 95% confidence intervals. The percentage of participants with neutralisation
145 against SARS-CoV-2 variants were analysed using a multivariable logistic regression model, with age, BMI,
146 ethnicity, and diabetes as covariates. All analyses were undertaken using SPSS v28, and a two-tailed p-
147 value <0.05 was taken to indicate statistical significance.

148

149 *Figures and Tables*

150 Graphical visualisations were created using Prism software (version 9.4.1). Antigenic cartography maps
151 were created using the Racmacs function (version 4.2.1) in R Studio, with inhibition data transformed to
152 mimic titre data.

153 *Results*

154 *Study Participants*

155 From 331 participants who were screened, the study enrolled 298 participants. A small number of
156 participants were excluded after enrollment (n = 2) or lost to follow up (n = 8) at different timepoints
157 (Figure 1). Twenty-eight days after second vaccination, 288 participants remained enrolled with 287
158 samples analysed [13]. At 6 months post second dose (prior to third dose), 273 participants remained in
159 the study with immunogenicity analysis performed on 239 (anti-S IgG analysis and anti-nucleocapsid
160 testing) and 236 (surrogate viral neutralisation testing) participants, respectively. At 28 days post third
161 dose, 236 of the remaining 257 participants had their samples analysed on all three assays (Figure 1). The
162 average duration of time from enrolment to serum collection at the 28-day post third dose timepoint was
163 238 days (approximately 8 months); this ranged from 174 days to 354 days.

164

165 *Demographics*

166 The study population includes several at risk New Zealand populations, with demographics summarised
167 in Table 1. Māori and Pacific populations comprise 29.9% and 28.1% of the study population compared to
168 approximately 17% and 8% of the total New Zealand population, respectively [15]. Half of the Pacific
169 study population are Samoan, with the second most prevalent Pacific ethnicity being Tongan (13.6%).
170 New Zealand European represent the largest proportion of non-Māori, non-Pacific participants making up
171 34.7% of the total study population. Māori and Pacific participants have a lower median age (50 years
172 and 42 years, respectively) compared to 70 years for New Zealand European. Almost 45% of the study
173 population are aged over 54 years, with 16.3% being 75 years or older. The BMI of participants ranges
174 from 18.8 kg/m² to 61.0 kg/m²; with 16% of participants having a healthy body weight and over half of
175 the study population being classified as obese (55.9%). 10% of the study population are diabetic, with
176 type 2 diabetes being the most prevalent (Table 1).

177

178 *Third Dose Vaccination and Laboratory Analysis Windows*

179 Participants received their third vaccination between 3.0 and 7.8 months after their second dose, with a

180 median of 5.7 months (Supplementary Figure 1). The collection of samples at the 28 days post third dose
181 timepoint ranged from 4 to 160 days post third dose. The sample collection had a preferred window of
182 21-56 days post third dose, with 85% percent of participants being within this window, with a median of
183 32 days. All samples (n = 4) collected <21 days post third dose were excluded from analysis
184 (Supplementary Figure 2). Variations in vaccination window or sample collection window (after 21 days)
185 did not have statistically significant effects on immunogenicity of binding antibody titres or neutralisation
186 responses in this cohort (Supplementary Table 2). However, this study was not powered to detect these
187 temporal differences.

188

189 *SARS-CoV-2 prior infection: nucleocapsid seropositivity*

190 At the time of sample analysis, there were very low rates of prior SARS-COV-2 infection in this cohort.
191 Three (1.3%) participants tested positive for anti-nucleocapsid antibodies prior to their third dose, which
192 increased to 11/236 (4.6%) 28 days post third dose. Statistical analysis showed the inclusion of these
193 participants did not significantly impact primary outputs of analysis (data not shown) and were included
194 in all subsequent analyses.

195

196 *SARS-CoV-2 Ancestral Anti-S IgG antibodies*

197 In the total study population, anti-S IgG GMT waned approximately 10-fold from 966 IU/mL 28 days post
198 second dose to 101 IU/mL 6 months post-second vaccine dose. This waning was statistically significant
199 and seen across all ethnicities, BMI, and age subgroups ($p < 0.001$, Figure 2). Comparing GMT 28 days post
200 second dose to 28 days post third dose, there was an increase from 966 IU/mL to 1892 IU/mL, equating
201 to an almost 2-fold rise in anti-S IgG antibodies following a third dose ($p < 0.001$, Figure 2).

202

203 All age groups had significant improvements in antibody titre from the third vaccine dose, compared to
204 28 days after second dose ($p < 0.001$ for all, Figure 3A). After a third vaccination, 16-34-year-olds GMT
205 increased almost 2-fold (1520.2 IU/mL to 2939.7 IU/mL), 35-54-year-olds increased 1.5-fold (1188.1
206 IU/mL to 1848.4 IU/mL), 55-64-year-olds increased 1.7-fold (1005 IU/mL to 1717.5 IU/mL), 65-74-year-

207 olds increased 2.8-fold (824.3 IU/mL to 2318.1 IU/mL) and 75+ year-olds increased 2.8-fold (421.3 IU/mL
208 to 1175 IU/mL, Figure 3A). When comparing the GMFR, (the level of SARS-CoV-2 anti-S IgG 6 months post
209 second dose relative to 28 days post third dose), participants aged 75 years and older showed the
210 greatest improvement (highest GMFR) after three doses. This difference was statistically significant
211 compared to three other ages groups, 16-34-year-olds ($p = 0.022$), 35-54-year-olds ($p = 0.002$) and 55-64-
212 year-olds ($p = 0.016$), but not compared to 65-74-year-olds (Table 2). All age data was adjusted for BMI,
213 ethnicity, and diabetes status.

214

215 A significant increase in GMT from 28 days post second dose to 28 days post third dose was seen across
216 some ethnic groups in the study ($p < 0.001$, Figure 3B). Non-Māori and non-Pacific peoples and Māori
217 both increased approximately 1.8-fold after three doses from 971.6 IU/mL to 1800.2 IU/mL and 1118
218 IU/mL to 2021.1 IU/mL, respectively. After three doses, Pacific peoples GMT increased 2.2-fold (832.3
219 IU/mL to 1871.8 IU/mL, Figure 3B). There was no statistically significant difference in GMT between
220 ethnicities at 6 months post second dose ($p = 0.308$) or 28 days post third dose ($p = 0.782$). However, the
221 GMFR (from 6 months post second dose relative to 28 days post third dose) was significantly higher in
222 Māori (GMFR = 3.44) compared to non-Māori and non-Pacific participants (GMFR = 2.41, $p = 0.0013$,
223 Table 2). All ethnicity data was adjusted for age, BMI, and diabetes status.

224

225 No significant difference was observed in the GMT between different BMI groups within the timepoints 6
226 months post second dose ($p = 0.113$), and 28 days post third dose ($p = 0.083$). However, for each BMI
227 subgroup analysed a significant increase in GMT from 28 days post second dose to 28 days post third
228 dose was seen ($p < 0.001$, Figure 3C). Participants with a BMI between 18.5 and 25.0 kg/m² (healthy
229 weight) had their GMT increase 1.8-fold from 1039.5 IU/mL 28 days post second dose to 1856.7 IU/mL 28
230 days post third dose. After three doses, GMT of overweight participants (BMI 25.0 kg/m² – 30.0 kg/m²)
231 increased approximately 2-fold (819.6 IU/mL to 1609.4 IU/mL). Similarly, participants with a BMI of >30.0
232 kg/m² (obese) had GMT increase approximately 2.2-fold (1061.2 IU/mL to 2279 IU/mL) after three doses
233 of BNT162b2 (Figure 3C). Consistently, the GMFR of the BMI subgroups comparing 6 months post second

234 dose to 28 days post third dose did not show clear statistically significant differences ($p = 0.05$). All BMI
235 data was adjusted for age, ethnicity, and diabetes status.

236

237 At 28 days and 6 months post second dose, diabetic participants showed significantly lower GMT
238 compared to non-diabetics ($p = 0.022$ and $p = 0.001$, respectively). Interestingly, 28 days post third dose,
239 there was no longer a statistical significance between GMT for participants with or without diabetes ($p =$
240 0.556). Diabetic participants had a 2.3-fold increase in GMT from 722.2 IU/mL 28 days post second dose
241 to 1764.8 IU/mL 28 days post third dose ($p < 0.001$, Figure 3D). This fold increase is higher than that
242 observed in non-diabetics, where there was a 1.7-fold increase in GMT (1210.9 IU/mL to 2035.8 IU/mL, p
243 < 0.001 , Figure 3D). The anti-S IgG GMFR in participants with diabetes, was significantly greater post third
244 dose (~4-fold change), compared to participants without (~2-fold change, $p = 0.042$, Table 2). All diabetes
245 data was adjusted for age, ethnicity, and BMI.

246

247 *Neutralising antibodies against SARS-CoV-2*

248 Neutralisation of the Ancestral variant waned from a median of 95.4% 28 days post second dose to 85.7%
249 6 months post second dose (Figure 4A). Beta variant neutralisation waned from 86.4% to 55.5% and Delta
250 variant from 96.0% to 73.8% 28 days post second dose and 6 months post vaccination, respectively
251 (Figure 4B & C). The primary two dose schedule of the Pfizer-BioNTech BNT162b2 vaccine did not induce
252 detectable levels of neutralisation against the SARS-CoV-2 Omicron BA.1 variant in most participants
253 (Figure 4D). At 28 days post second dose, 12.9% of participants had detectable neutralisation against
254 Omicron BA.1 which reduced to 4.2% 6 months post second dose (Supplementary Table 3). After the
255 third dose, Omicron BA.1 neutralisation levels were detectable in 88.1% of participants (Figure 4D,
256 Supplementary Table 3).

257

258 Antigenic cartography illustrates the degree of antigenic difference between viral variants based on the
259 antibody responses in sera (Figure 5). Following the third vaccination a convergence of antigens,
260 particularly for Ancestral, Beta and Delta variants was observed. The antigenic difference between these

261 three variants and Omicron BA.1 also reduced following the third dose, compared to after two doses.

262 This is indicative of an increase in serum antibodies that cross-neutralise Omicron, following three doses
263 of the vaccine compared with a primary (two dose) vaccination course.

264

265 Given the predominance of circulating variants at the time this study was conducted, we examined the
266 change in Omicron BA.1 neutralisation response in more detail. There was a significant increase in
267 detectable Omicron BA.1 % inhibition from 6 months post second dose to 28 days post third dose, across
268 the study population (Figure 6A-D, Table 3). Age was the only demographic variable for which the
269 increase in Omicron BA.1 response differed. The mean neutralisation in 16-34-year-olds was significantly
270 higher after three doses (82.7%) compared to 35-54-year-olds (72.3%, $p = 0.016$), 55-64-year-olds (71.1%,
271 $p = 0.016$), 65-74-year-olds (70.5%, $p = 0.043$) and 75+ year-olds (63.0%, $p = 0.001$) (Table 3). Data was
272 adjusted for ethnicity, BMI, and diabetes status. There was no statistically significant difference in mean
273 Omicron BA.1 neutralisation response between different ethnicity groups, BMI ranges, or diabetes status
274 after three vaccine doses (Table 3).

275

276

277 *Discussion*

278 It is becoming increasingly difficult to predict population level SARS-CoV-2 immunity given variations in
279 vaccination and prior infection history around the globe. This study cohort contributes to the growing
280 body of international research surrounding the immunogenicity of three doses of the Pfizer-BioNTech
281 BNT162b2 COVID-19 vaccine. It provides unique insight into rarely observed infection naïve populations,
282 including ethnicities not explored elsewhere. Understanding the results of this study will help to inform
283 mRNA vaccination schedules in future pandemics where the global population is naïve to a virus with
284 relatively high rates of mutation.

285

286 An important finding from these analyses is that the third dose of Pfizer-BioNTech BNT162b2 vaccine was
287 able to significantly increase the mean SARS-CoV-2 anti-S IgG titres of all demographic groups above
288 titres found 28 days post dose two. While two doses in diabetics did not result in comparable titres to
289 non-diabetics, the third vaccine dose removed this discrepancy, and is a significant finding. Furthermore,
290 all demographic groups are afforded a substantial neutralising antibody response (over 50%
291 neutralisation in the sVNT assay) to the Omicron BA.1 variant from the third vaccine dose that two doses
292 were unable to provide. This is noteworthy as the Omicron BA.1 sequence is not included in the Ancestral
293 based BNT162b2 vaccine and the vast majority of the study cohort were infection naïve at the time of
294 testing.

295

296 Older age groups, such as those aged 75 years or older, in this cohort appear to have a more complex
297 response to the third vaccine dose. At each timepoint they have significantly lower SARS-CoV-2 anti-S IgG
298 titres compared to younger age groups. However, like their younger comparators, they have significant
299 improvement in GMTs after three doses compared to two doses, which mirrors results of another study
300 [16]. Comparing GMT 6 months post second dose to 28 days post third dose, 75+ year-olds receive the
301 greatest benefit from the third vaccine dose. However, the ability of 75+ age group to neutralise variant
302 Omicron BA.1 is reduced compared to younger age groups.

303

304 Waning immunity was seen in this cohort with both anti-S IgG antibody levels and neutralising responses
305 reducing over a 3-6-month period after dose two of BNT162b2. Interestingly, there was a clear
306 consistency in waning of anti-S IgG antibody titres across age, ethnicity, and BMI which contrasts with
307 other published data [17]. Prior international research has shown a greater rate of waning in older age
308 groups (60 years and over)[17], as well as those with , as well as higher BMI (>40.0 kg/m²after) after two
309 doses of vaccine [18]. It is unclear if the differences with published literature are due to the unique ethnic
310 groups within New Zealand, and this study population, the lack of circulating SARS-CoV-2 in New Zealand
311 at the time of the study, or from differences in study design and testing.

312

313 Data on immune responses to COVID-19 vaccines in diabetics has been contradictory [19]. In contrast to
314 other demographic subgroups in this cohort, participants with diabetes exhibited a greater waning at 6
315 months post second dose. Despite lower antibody levels after two doses in diabetic participants, the
316 difference in antibody titres were corrected following a third dose, to equivalent levels as the non-
317 diabetics in our study. This is a significant study finding and proves a third vaccine dose is of particular
318 importance for diabetics in New Zealand.

319

320 Despite the early success and elimination of SARS-CoV-2 in New Zealand, there was a significant increase
321 in community transmission as third doses were being administered in New Zealand, initially with the
322 Delta variant (predominantly in the Auckland region) and then with the Omicron variant (nationwide) [3].
323 However, only a small proportion of our study participants had evidence of infection, therefore it was not
324 possible to assess the impact of hybrid immunity on immunogenicity in this cohort. Nucleocapsid
325 seroprevalence was used as a surrogate marker of previous SARS-CoV-2 infection. There are limitations in
326 relying upon this marker as some individuals may not mount a nucleocapsid antibody response following
327 SARS-CoV-2 infection, particularly if previously vaccinated, and these antibodies have been observed to
328 wane over time [13, 20-22]. However, waning of anti-nucleocapsid antibodies is assay dependent, with
329 the Roche total anti-nucleocapsid antibody assay, used in this study, reported to show high sensitivity out
330 to at least 11.5 months post infection [23]. Participants were also screened at study commencement for

331 nucleocapsid seroprevalence to ensure our population was infection naïve prior to participation.

332 Therefore, the number of participants with detectable anti-nucleocapsid antibodies in this study is likely

333 to represent the true number of study participants with prior infection, increasing validity of our results.

334

335 This study presents a unique and important perspective on response to the original BNT162b2 COVID-19

336 vaccine, in an infection naïve setting compared to populations with high rates of prior or intercurrent

337 infection internationally [17, 24]. Conflicting studies indicate that the order of when infection and

338 vaccination occur has an impact on antibody titres from vaccination, specifically infection prior to

339 vaccination can decrease [24] or increase titres [25] and therefore protection. It is also known that

340 natural infection with one variant, such as Omicron BA.1, may not be sufficient to protect from other

341 variants, such as Omicron BA.2 [26]. Data from the New Zealand Ministry of Health shows that New

342 Zealanders who had received three or more doses of BNT162b2 had a 66% reduction in the risk of death

343 [9]. The emergent cross neutralisation from three BNT162b2 doses, as observed in this study, likely

344 protects against the severe consequences of subsequent infections, particularly with Omicron variants.

345 One theory for how this Omicron BA.1 neutralisation arose from a third dose, is the preferential

346 maturation of antibodies specific to the RBD portion of the spike protein, where there are less

347 dissimilarities between the Ancestral and Omicron variants [27].

348

349 The induction of Omicron BA.1 cross neutralisation in this cohort is consistent with previous literature

350 that shows increased antibody titres and neutralisation after three doses against Omicron variants [28,

351 29] however, this is reduced in populations over 65 years of age [28]. Older groups in this study (65-74

352 and 75+ years-old) showed reduced antibody titres and neutralisation capacity following three doses,

353 raising concerns that these populations are less protected from new variants. Bivalent vaccines, which

354 encode both Ancestral and Omicron spike protein, may be able to abrogate these effects in the elderly.

355

356 Our data shows the strong ability of a third BNT162b2 vaccine dose, in a setting with limited natural

357 infection and hybrid immunity, to produce a neutralising response against the Omicron BA.1 variant

358 regardless of age, BMI, ethnicity, or presence or absence of diabetes. Ka Mātau, Ka Ora is an ongoing
359 cohort study and will continue to monitor the differences seen in immunogenicity, as participants
360 develop hybrid immunity following infection with different variants of concern, and antibody waning
361 alongside cellular immune responses.

Acknowledgements

We would like to acknowledge the study participants and the study teams at both sites for their commitment to the study, including Michelle Sampson (Lead Clinical Coordinator Lakeland Clinical Trials), Nina Linton (Study Coordinator Lakeland Clinical Trials), Gary Lees (Director of Nursing and Midwifery Lakes District Health Board), Ali Maoate (Study Coordinator Southern Clinical Trials), Dr Monica Nua George (Medical Director Etu Pasifika). Dr Api Talemaitoga provided input on study design and engaging Pacific peoples in the study. The Te Urungi Māori Advisory group of Malaghan Institute of Medical Research (MIMR) provided input on engaging Māori in the study. Mr John Treanor provided Māori consultation for the Lakeland Clinical Trials site. Dr Matea Gillies was the Māori advisor, Ngai Tahu. Dr Peter McIntyre provided peer review of the study protocol for HDEC review. Giulia Giunti and Bethany Andrews at MIMR provided operational support for the study. Ciara Ramiah provided laboratory assistance at the University of Auckland.

Author Contributions

MB, FP, JU, KW, and GLG developed the study concept. FP, MB, and BL developed the study protocol. Study conduct, data and sample collection was overseen by MW and SC. BL, CH, and KG oversaw study coordination and data management. NM, RM, and AP ran and analysed the surrogate viral neutralisation assay. CF, CH, and BL lead the data and statistical analysis. BL, CH, CF, and MB wrote the report. Each author provided valuable feedback and revisions to the publication.

Conflicts of Interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: James Ussher reports financial support was provided by New Zealand Ministry of Business Innovation and Employment, Michael Williams reports financial support was provided by Malaghan Institute of Medical Research, Simon Carson reports financial support was provided by Malaghan Institute of Medical Research, Graham Le Gros reports financial support was provided by New Zealand Ministry of Business Innovation and Employment, Frances Priddy reports financial support was provided by New Zealand Ministry of Business Innovation and Employment. Frances

Priddy reports financial support was provided by New Zealand Ministry of Health. Frances Priddy reports a relationship with Janssen Pharmaceuticals Inc that includes consulting or advisory.

References

1. World Health Organisation. *WHO Director-General's statement on IHR Emergency Committee on Novel Coronavirus (2019-nCoV)*. 2020 [cited 2022 25 November]; Available from: [https://www.who.int/director-general/speeches/detail/who-director-general-s-statement-on-ih-er-emergency-committee-on-novel-coronavirus-\(2019-ncov\)](https://www.who.int/director-general/speeches/detail/who-director-general-s-statement-on-ih-er-emergency-committee-on-novel-coronavirus-(2019-ncov)).
2. New Zealand Government. *Prime Minister: COVID-19 Alert Level increased*. 2020 [cited 2022 14 December]; Available from: <https://www.beehive.govt.nz/speech/prime-minister-covid-19-alert-level-increased>.
3. Ministry of Health, *More than 40,000 booster doses given yesterday; 24 community cases; 8 in hospital*. 2022, Ministry of Health: www.health.govt.nz.
4. Ministry of Health. *COVID-19 update, 17 August*. 2021 [cited 2022 14 December]; Available from: <https://www.health.govt.nz/news-media/news-items/covid-19-update-17-august>.
5. Ministry of Health, *Boosters key to protecting New Zealanders from Omicron in 2022*. 2022: www.health.govt.nz.
6. ESR, *COVID-19 Genomics Insights Dashboard (CGID) #14 - 7 July 2022*. 2022, ESR
7. ESR, *COVID-19 Genomics Insights Dashboard (CGID) #36 - 17 March 2023*. 2023, ESR.
8. Harrison, S.L., et al., *Comorbidities associated with mortality in 31,461 adults with COVID-19 in the United States: A federated electronic medical record analysis*. PLOS Medicine, 2020. **17**(9): p. e1003321.
9. Public Health Agency, *COVID-19 Mortality in Aotearoa New Zealand: Inequities in Risk*. 2022, Ministry of Health: Wellington: Ministry of Health.
10. Priddy, F.H., et al., *Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults*. Vaccine, 2022. **40**(34): p. 5050-5059.
11. Ministry of Health, *HISO 10001:2017 Ethnicity Data Protocols*. 2017: Wellington: Ministry of Health.
12. Ministry of Health. *Body Size*. 2018 [cited 2022 25 November]; Available from: <https://www.health.govt.nz/our-work/populations/maori-health/tatau-kahukura-maori-health-statistics/nga-tauwehe-tuono-me-te-marumaru-risk-and-protective-factors/body-size>.
13. Priddy, F.H., et al., *Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults*. 2022(1873-2518 (Electronic)).
14. Meyer, B., et al., *Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT)*. Emerg Microbes Infect, 2020. **9**(1): p. 2394-2403.
15. Statistics New Zealand. *A case study of 2018 Census ethnic group summaries: MELAA*. 2018 [cited 2022 14 December]; Available from: <https://www.stats.govt.nz/news/ethnic-group-summaries-reveal-new-zealands-multicultural-make-up/>.
16. Falsey, A.R., et al., *SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3*. New England Journal of Medicine, 2021. **385**(17): p. 1627-1629.
17. Pérez-Alós, L., et al., *Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors*. Nature Communications, 2022. **13**(1): p. 1614.
18. van der Klaauw, A.A., et al., *Accelerated waning of the humoral response to SARS-CoV-2 vaccines in obesity*. medRxiv, 2022: p. 2022.06.09.22276196.
19. Boroumand, A.B., et al., *Immunogenicity of COVID-19 vaccines in patients with diabetes mellitus: A systematic review*. Front Immunol, 2022. **13**: p. 940357.
20. Whitcombe, A.L., et al., *Comprehensive analysis of SARS-CoV-2 antibody dynamics in New Zealand*. Clin Transl Immunology, 2021. **10**(3): p. e1261.

21. McGregor, R., et al., *The persistence of neutralising antibodies up to 11 months after SARS CoV-2 infection in the southern region of New Zealand*. N Z Med J, 2022. **135**(1550): p. 162-166.
22. Craigie, A., et al., *SARS-CoV-2 antibodies in the Southern Region of New Zealand, 2020*. Pathology, 2021. **53**(5): p. 645-651.
23. Coppola, A., et al., *Durability of Humoral Immune Responses to SARS-CoV-2 in Citizens of Ariano Irpino (Campania, Italy): A Longitudinal Observational Study With an 11.5-Month Follow-Up*. Front Public Health, 2021. **9**: p. 801609.
24. Anderson, M., et al., *SARS-CoV-2 Antibody Responses in Infection-Naive or Previously Infected Individuals After 1 and 2 Doses of the BNT162b2 Vaccine*. JAMA Network Open, 2021. **4**(8): p. e2119741-e2119741.
25. Carazo, S., et al., *Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA–Vaccinated and Nonvaccinated Individuals in Quebec, Canada*. JAMA Network Open, 2022. **5**(10): p. e2236670-e2236670.
26. Trombetta, C.M., et al., *Immune response to SARS-CoV-2 Omicron variant in patients and vaccinees following homologous and heterologous vaccinations*. Communications Biology, 2022. **5**(1): p. 903.
27. Cameroni, E., et al., *Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift*. Nature, 2022. **602**(7898): p. 664-670.
28. Lassaunière, R., et al., *Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant (BA.1) 1 to 18 Weeks After the Second and Third Doses of the BNT162b2 mRNA Vaccine*. JAMA Network Open, 2022. **5**(5): p. e2212073-e2212073.
29. Haveri, A., et al., *Neutralizing antibodies to SARS-CoV-2 Omicron variant after third mRNA vaccination in health care workers and elderly subjects*. European Journal of Immunology, 2022. **52**(5): p. 816-824.




Figure 1. Participant flow-through of the Ka Mātau, Ka Ora study to date. Created with BioRender.com.

Table 1

Demographics of all participants included in analysis at any timepoint.

	% (n)	Median age (IQR)
<i>Total Participants</i>	288	52 (35 – 66)
<i>Gender</i>		
Female	54.2 (156)	50 (34 – 65)
Male	45.5 (131)	54 (39 – 66)
Non-Binary	0.3 (1)	31
<i>Age (years)</i>		
16-34	25.0 (72)	-
35-54	30.6 (88)	-
55-64	19.1 (55)	-
65-74	9.0 (26)	-
75+	16.3 (47)	-
<i>Ethnicity</i>		
Non-Māori and Non-Pacific Peoples	42.0 (121)	60 (49 – 76)
NZ European	82.6 (100)	70 (49 – 77)
Other	17.4 (21)	54 (46 – 59)
Māori	29.9 (86)	50 (35 – 59)
Pacific Peoples	28.1 (81)	42 (26 – 52)
Samoan	56.8 (46)	43 (26 – 56)
Tongan	13.6 (11)	32 (21 – 45)
Tokelauan	11.1 (9)	49 (37 – 55)
Cook Island Māori	8.6 (7)	48 (32 – 52)
Fijian	6.2 (5)	36 (28 – 47)
Other	3.7 (3)	38 (38 – 41)
<i>BMI</i>		
Healthy	16.0 (46)	49 (23 – 67)
Overweight	28.1 (81)	54 (38 – 63)
Obese	55.9 (161)	51 (38 – 63)
<i>Diabetes Status</i>		
Present	9.7 (28)	58 (50 – 72)
Absent	90.3 (260)	50 (33 – 63)

Other non-Māori and non-Pacific peoples includes European not further defined (8), British (7), South African (3), Dutch (2), Middle Eastern/Latin American/African (1).

Other Pacific peoples includes Kiribati (1), Tuvalu (1), Cook Island Māori/Samoan (1).

Healthy BMI 18.5 kg/m² - 24.9 kg/m²; Overweight BMI 25.0 kg/m² - 29.9 kg/m²; Obese BMI ≥ 30.0 kg/m².

Diabetes type 1 (2), type 2 (26).




Figure 2. Unadjusted SARS-CoV-2 anti-S IgG antibody titres, for all study participants after two and three doses of BNT162b2 vaccine. Cut off for positive result is 7.1 IU/mL (horizontal dotted line).

*** $p < 0.001$ comparing each group to each other




Figure 3. SARS-CoV-2 anti-S IgG geometric mean titres, for key demographic groups, after two and three doses of BNT162b2 vaccine, adjusted for age, BMI, ethnicity, and diabetes status (95% CI).

*** $p < 0.001$ for all subgroups comparing timepoints indicated.

Table 2

SARS-CoV-2 anti-S IgG antibody titre geometric mean fold rise after three doses of BNT162b2 vaccine, adjusted for age, ethnicity, BMI, and diabetes status.

	<i>28 days post third dose compared to 6 months post second dose</i>		
	<i>% (n)</i>	<i>GMFR</i>	<i>95% CI</i>
<i>Total participants</i>	208	2.99	2.39 – 3.74
<i>Age (years)</i>			
16-34	20.2 (42)	2.60 *	1.86 – 3.64
35-54	31.7 (66)	2.35 **	1.79 – 3.10
55-64	22.6 (47)	2.65 *	1.93 – 3.62
65-74	10.6 (22)	3.41	2.32 – 5.02
75+	14.9 (31)	4.31	2.97 – 6.24
<i>Ethnicity</i>			
Non-Māori, Non-Pacific Peoples	48.6 (101)	2.41	1.86 – 3.12
Māori	33.6 (70)	3.44 †	2.55 – 4.65
Pacific Peoples	17.8 (37)	3.21	2.32 – 4.44
<i>BMI</i>			
Healthy	14.4 (30)	2.44	1.69 – 3.53
Overweight	32.7 (68)	2.95	2.23 – 3.91
Obese	52.9 (110)	3.97	2.70 – 4.60
<i>Diabetes</i>			
Present	9.1 (19)	3.73 ‡	2.50 – 5.60
Absent	90.9 (189)	2.39	2.02 – 2.83

Healthy BMI 18.5 kg/m² - 24.9 kg/m²; Overweight BMI 25.0 kg/m² - 29.9 kg/m²; Obese BMI ≥ 30.0 kg/m².

GMFR = geometric mean fold rise

* p < 0.05 compared to 75+ years.

** p < 0.01 compared to 75+ years.

† p < 0.05 compared to non-Māori, non-Pacific peoples.

‡ p < 0.05 compared to absent.




Figure 4. Unadjusted SARS-CoV-2 neutralising antibody responses to Ancestral, Beta, Delta and Omicron BA.1 variants after two and three doses of BNT162b2 vaccine. Cut-off for detectable result is 20% inhibition (horizontal dotted line).




Figure 5. Antigenic cartography map displaying variants of concern (solid-coloured symbols) before and after three doses of BNT162b2 vaccine. Lined arrow distances between VoC (Ancestral, Beta, Delta, and Omicron BA.1) indicate shift in antigenic similarity using neutralising antibody (% inhibition). Individual sera are represented by hollow squares.




Figure 6. Unadjusted mean SARS-CoV-2 neutralising antibody responses to Omicron BA.1 variant, for key demographic groups, after two and three doses of BNT162b2 vaccine. Cut-off for detectable result is 20% inhibition (horizontal dotted line).

Table 3

SARS-CoV-2 Omicron BA.1 neutralising antibody responses after three doses of BNT162b2 vaccine, adjusted for age, ethnicity, BMI, and diabetes status.

	28 days post third dose			Change in Percent Inhibition (28 days post third dose compared to 6 months post second dose)			
	% (n)	Mean % Inhibition	95% CI	% (n)	Δ in % Inhibition	95% CI	p-value
<i>Total participants</i>	236			209			
<i>Age (years)</i>							
16-34	19.1 (45)	82.7	75.0 – 88.0	20.1 (42)	64.2	53.4 – 75.0	0.243
35-54	31.8 (75)	72.3*	62.4 – 79.6	32.1 (67)	59.2	50.4 – 68.0	
55-64	20.8 (49)	71.1*	58.8 – 79.8	22.5 (47)	52.8	42.7 – 63.0	
65-74	9.7 (23)	70.5*	53.9 – 81.1	10.5 (22)	52.7	40.3 – 65.2	
75+	18.6 (44)	63.0**	45.9 – 74.7	14.8 (31)	51.3	39.3 – 63.3	
<i>Ethnicity</i>							0.544
Non-Māori, Non-Pacific Peoples	48.3 (114)	69.7	59.9 – 77.1	48.3 (101)	54.2	45.9 – 62.6	0.211
Māori	30.5 (72)	73.1	62.6 – 80.7	34.0 (71)	59.0	49.3 – 62.6	
Pacific Peoples	21.2 (50)	75.5	65.7 – 82.5	17.7 (37)	54.9	44.5 – 65.4	
<i>BMI</i>							0.211
Healthy	14.0 (33)	70.2	55.1 – 80.2	15.3 (30)	53.8	41.9 – 65.7	0.275
Overweight	32.6 (77)	70.1	59.3 – 78.0	32.5 (68)	53.7	44.6 – 62.8	
Obese	53.4 (126)	77.6	71.8 – 82.2	53.2 (111)	60.7	53.6 – 67.8	
<i>Diabetes Status</i>							0.275
Present	9.7 (23)	69.1	52.1 – 80.1	9.1 (19)	59.9	54.5 – 65.4	0.275
Absent	90.3 (213)	76.2	71.8 – 79.9	90.9 (190)	52.2	39.1 – 65.3	

Healthy BMI 18.5 kg/m² - 24.9 kg/m²; Overweight BMI 25.0 kg/m² - 29.9 kg/m²; Obese BMI ≥ 30.0 kg/m².

Diabetes status: 28 days post third dose - Type 1 (1), Type 2 (22). 28 days post third dose compared to 6 months post second dose – Type 1 (1), Type 2 (18).

* p < 0.05 compared to 16-34 years.

** p < 0.01 compared to 16-34 years.